Cationized gelatin-HVJ envelope with sodium borocaptate improved the BNCT efficacy for liver tumors in vivo

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Fujii, Hitoshi ^a   Matsuyama, Akifumi ^b   Komoda, Hiroshi ^a   Sasai, Masao ^b   Suzuki, Minoru ^c   Asano, Tomoyuki ^d   Doki, Yuichiro ^a   Kirihata, Mitsunori ^d   Ono, Koji ^c   Tabata, Yasuhiko ^e   Kaneda, Yasufumi ^a   Sawa, Yoshiki ^a   Lee, Chun Man ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d Osaka Prefecture University   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOROCAPTATE; GELATIN; BORANE DERIVATIVE; CATION; DRUG CARRIER; THIOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION; IN VIVO STUDY; LIVER TUMOR; MALE; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; SENDAI VIRUS; TUMOR CELL; TUMOR GROWTH; VIRUS ENVELOPE; ZETA POTENTIAL; ANIMAL; C3H MOUSE; CANCER TRANSPLANTATION; CARCINOMA; CHEMISTRY; EVALUATION; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE; VIRUS CAPSID;

ANIMALS; BOROHYDRIDES; BORON NEUTRON CAPTURE THERAPY; CAPSID; CARCINOMA; CATIONS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GELATIN; LIVER NEOPLASMS; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; SENDAI VIRUS; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 78651594821     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-8     Document Type: Article

References (45)

1. Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005, 11:3987-4002. 10.1158/1078-0432.CCR-05-0035, 15930333.
2. Yamamoto T, Nakai K, Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett 2008, 262:143-52. 10.1016/j.canlet.2008.01.021, 18313207.
3. Pinelli T, Zonta A. From the first idea to the application to the human liver. 2002, Research and development in Neutron Capture Therapy.
4. Suzuki M, Sakurai Y, Hagiwara S, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Kudo M, Ono K. First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol 2007, 37:376-81. 10.1093/jjco/hym039, 17578894.
5. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser G, Jockel KH, Sauerwein W. BNCT in liver metastases: results of the EORTC trial 11001. Strahlentherapie Und Onkologie 2007, 183:115-115.
6. Sauerwein W, Malago M, Moss R, Altieri S, Hampel G, Wittig A, Nievaart V, Collette L, Mauri P, Huiskamp R, Michel J, Daquino G, Gerken G, Bornfeld N, Broelsch CE. Boron Neutron Capture Therapy (BNCT) for the treatment of diffuse, non-resectable liver metastases. Strahlentherapie Und Onkologie 2006, 182:109-109.
7. Cardose JE, Trivillin VA, Heber EM, Nigg DW, Calzetta O, Blaumann H, Longhino J, Itoiz ME, Bumaschny E, Pozzi E, Schwint AE. Effect of Boron Neutron Capture Therapy (BNCT) on normal liver regeneration: Towards a novel therapy for liver metastases. International Journal of Radiation Biology 2007, 83:699-706. 10.1080/09553000701570212, 17729164.
8. Chou FI, Chung HP, Liu HM, Chi CW, Lui WY. Suitability of boron carriers for BNCT: Accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA. Applied Radiation and Isotopes 2009, 67:S105-108. 10.1016/j.apradiso.2009.03.025, 19375330.
9. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, Kaiser GM, Jockel KH, Schmid KW, Ortmann U, Sauerwein WA. Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). Int J Cancer 2008, 122:1164-71. 10.1002/ijc.23224, 17985341.
10. Suzuki M, Masunaga SI, Kinashi Y, Takagaki M, Sakurai Y, Kobayashi T, Ono K. The effects of boron neutron capture therapy on liver tumors and normal hepatocytes in mice. Jpn J Cancer Res 2000, 91:1058-64.
11. Sakurai Y, Ono K, Miyatake S, Maruhashi A. Improvement effect on the depth-dose distribution by CSF drainage and air infusion of a tumour-removed cavity in boron neutron capture therapy for malignant brain tumours. Phys Med Biol 2006, 51:1173-83. 10.1088/0031-9155/51/5/009, 16481686.
12. Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, Backer JM. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem 2006, 6:167-84. 10.2174/187152006776119153, 16529539.
13. Mehta SC, Lu DR. Targeted drug delivery for boron neutron capture therapy. Pharm Res 1996, 13:344-51. 10.1023/A:1016076022267, 8692724.
14. Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kibayashi H, Eriguchi M, Yanagie H. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 2004, 98:195-207. 10.1016/j.jconrel.2004.04.018, 15262412.
15. Masunaga S, Kasaoka S, Maruyama K, NIgg D, Sakurai Y, Nagata K, Suzuki M, Kinashi Y, Maruhashi A, Ono K. The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-(10)B (GB-10) as (10)B-carriers for boron neutron capture therapy. Int J Radiat Oncol Biol Phys 2006, 66:1515-22. 10.1016/j.ijrobp.2006.08.028, 17126210.
16. Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S. Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 2008, 87:287-94. 10.1007/s11060-008-9522-8, 18219552.
17. Aljabiri MR, Lodato F, Burroughs AK. Surveillance and diagnosis for hepatocellular carcinoma. Liver Transpl 2007, 13(11 Suppl 2):S2-12. 10.1002/lt.21324, 17969087.
18. World Health Organization World Health Statistics 2008/Future trends in global mortality. World Health Organization., http://www.who.int/whosis/whostat/2008/en/index.html
19. Arciero CA, Sigurdson ER. Diagnosis and treatment of metastatic disease to the liver. Semin Oncol 2008, 35:147-59. 10.1053/j.seminoncol.2007.12.004, 18396200.
20. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002, 6:219-26. 10.1006/mthe.2002.0647, 12161188.
21. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006, 5:1021-8. 10.1158/1535-7163.MCT-05-0352, 16648574.
22. Kawano H, Komaba S, Kanamori T, Kaneda Y. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Med 2007, 5:1-7. 10.1186/1741-7015-5-28, 1785383, 17198546.
23. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007, 67:227-36. 10.1158/0008-5472.CAN-06-1615, 17210703.
24. Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008, 57:73-84. 10.1007/s00262-007-0351-y, 17602226.
25. Mima H, Tomoshige R, Kanamori T, Tabata Y, Yamamoto S, Ito S, Tamai K, Kaneda Y. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 2005, 7:888-97. 10.1002/jgm.735, 15712245.
26. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998, 76:418-422. 10.1002/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.0.CO;2-5, 9579581.
27. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 2002, 62:4282-8.
28. Fukunaka Y, Iwanaga K, Morimoto K, Kakemi M, Tabata Y. Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation. J Control Release 2002, 80:333-43. 10.1016/S0168-3659(02)00026-3, 11943409.
29. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Ultrasound enhancement of in vitro transfection of plasmid DNA by a cationized gelatin. J Drug Target 2002, 10:193-204. 10.1080/10611860290022624, 12075820.
30. Nagata I, Kimura Y, Ito Y, Tanaka T. Temperature-Sensitive Phenomenon of Viral Maturation Observed in BHK Cells Persistently Infected with HVJ. Virology 1972, 49:453-461. 10.1016/0042-6822(72)90497-7, 4559687.
31. Guttenberger M. Protein Determination. Cell Biology 295-303. A Laboratory Handbook.
32. Ogura K, Yanagie H, Eriguchi M, Lehmann EH, Kuhne G, Bayon G, Kobayashi H. Neutron capture autoradiographic study of the biodistribution of 10B in tumor-bearing mice. Appl Radiat Isot 2004, 61:585-90. 10.1016/j.apradiso.2004.03.084, 15246403.
33. Saga K, Tamai K, Kawachi M, Shimbo T, Fujita H, Yamazaki T, Kaneda Y. Functional modification of Sendai virus by siRNA. J Biotechnol 2008, 133:386-94. 10.1016/j.jbiotec.2007.10.003, 18093677.
34. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-84. 10.1016/S0168-3659(99)00248-5, 10699287.
35. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res 2002, 8:1172-1181. Clin Cancer Res 2002;8:955-6.
36. Yanagie H. Selective Enhancement of Boron Accumulation with Boron-Entrapped Water-in-oil-in-water Emulsion in VX-2 Rabbit Hepatic Cancer Model for BNCT. 2006, Proc of 12th International Congress of Neutron Capture Therapy.
37. Ye SJ. Monte Carlo based protocol for cell survival and tumour control probability in BNCT. Phys Med Biol 1999, 44:447-61. 10.1088/0031-9155/44/2/012, 10070794.
38. Kobayashi T, Kanda K. Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy. Radiat Res 1982, 91:77-94. 10.2307/3575817, 7100396.
39. Kinashi Y, Masunaga S, Nagata K, Suzuki M, S T, Ono K. A bystander effect observed in boron neutron capture therapy: A study of the induction of mutations in the HPRT locus. Int J Radiat Oncol Biol Phys 2007, 68:508-14. 10.1016/j.ijrobp.2007.02.002, 17418970.
40. Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Ono K. Dosimetric study of boron neutron capture therapy with borocaptate sodium (BSH)/lipiodol emulsion (BSH/lipiodol-BNCT) for treatment of multiple liver tumors. Int J Radiat Oncol Biol Phys 2004, 58:892-6. 10.1016/j.ijrobp.2003.09.084, 14967447.
41. Suzuki M, Nagata K, Masunaga S, Kinashi Y, Sakurai Y, Maruhashi A, Ono K. Biodistribution of 10B in a rat liver tumor model following intra-arterial administration of sodium borocaptate (BSH)/degradable starch microspheres (DSM) emulsion. Appl Radiat Isot 2004, 61:933-7. 10.1016/j.apradiso.2004.05.014, 15308171.
42. Yanagie H, Tomita T, Kobayashi H, Fujii Y, Nonaka Y, Saegusa Y, Hasumi K, Eriguchi M, Kobayashi T, Ono K. Inhibition of human pancreatic cancer growth in nude mice by boron neutron capture therapy. Br J Cancer 1997, 75:660-5. 10.1038/bjc.1997.118, 2063329, 9043021.
43. Yanagie H, Sakurai Y, Ogura K, Kobayashi T, Furuya Y, Sugiyama H, Kobayashi H, Ono K, Nakagawa K, Takahashi H, Nakazawa M, Eriguchi M. Evaluation of neutron dosimetry on pancreatic cancer phantom model for application of intraoperative boron neutron-capture therapy. Biomed Pharmacother 2007, 61:505-14. 10.1016/j.biopha.2006.12.008, 17614250.
44. Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Ono K. A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity. Jpn J Clin Oncol 2007, 37:245-9. 10.1093/jjco/hym022, 17513310.
45. Kawano H, Komaba S, Yamasaki T, Maeda M, Kimura Y, Maeda A, Kaneda Y. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemother Pharmacol 2008, 61:973-8. 10.1007/s00280-007-0553-1, 17653716.